Daniel J Wallace, MD

Specialties & Experience of this Expert Witness

Additional Information

I have been practicing clinical rheumatology since 1979 with a special interest in systemic lupus erythematosus (SLE). I was fortunate to take over the clinic of Dr. Edmund Dubois on his passing in 1985 and developed the largest single practitioner lupus cohort in the United States. In collaboration with Cedars-Sinai Medical Center, our institution has participated in SLICC, the Lupus Clinical Trial Consortium, and several disease criteria committees. I have been the editor of the last 7 editions of Dubois Lupus Erythematosus; the patient handbook “The Lupus Book”, has sold more than 135,000 copies. Our center has performed over 150 lupus clinical trials, biomarker, genetics, quality of life and observational studies which has resulted in 450 peer-reviewed publications and 54 books/book chapters. I have had first authorship on manuscripts relating to celecoxib, mycophenolate mofetil, leflunomide, baritcitinib, belimumab and epratuzumab and 8 publications (6 as lead author) in the New England Journal of Medicine and the Lancet. I was the lead author of the BICLA (British Isles Cumulative Lupus Activity) index, which is the most commonly used primary outcome measure in lupus clinical trials. My efforts have resulted in raising over $20 million for lupus research and establishing an endowed chair in rheumatology. I am excited by the prospect of participating in lupus research initiatives, and Cedars-Sinai Medical Center has the patients, technical expertise, coordinators and facilities to do an outstanding job in carry out this study. Since 2010, I have participated in training 25 rheumatology fellows as Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai. I am enthusiastic about participating in the transmegnetic stimulation study.